Last Updated on May 26, 2026
⚠️ 2026 update on CGRP medications for migraine
This media segment is from 2021, when Emgality had just become PBS-listed and the other CGRP options were still on a private prescription. The landscape has changed significantly. In 2026:
- 3 CGRP medications are PBS-listed in Australia: Emgality (galcanezumab), Ajovy (fremanezumab) and Vyepti (eptinezumab — IV).
- Aimovig (erenumab) is registered in Australia but is not PBS-subsidised; full private cost applies.
- PBS criteria require chronic migraine with ≥8 headache days per month, failed ≥3 oral preventatives, neurologist prescription, and not concurrently on PBS Botox.
For the current 2026 picture, please read: CGRP Medications for Migraine in 2026 — Emgality, Ajovy, Vyepti and Aimovig — or visit Sydney Headache Centre — CGRP therapies.
I was very happy to help once again with Migraine Awareness Month, this time talking with Migraine Australia’s and VeDA Ambassador Alicia about vestibular migraine and how to manage it.
The key issues we discuss are the diagnosis of vestibular migraine, the investigations that can be helpful and then the treatment approach, looking at both medication and non-pharmacological treatments.
It is important to remember that the treatment approaches keep growing and that we should not give up after a few failed attempts.
Finally, a reminder to complete the vestibular migraine 2021 survey, which will be collated to help offer a broader overview of treatment strategies that have helped others. Just click HERE to get started, it will take you 5 minutes…